24/7 Market News – (AMEX:CANF) shares are surging this morning up more than 20% on news that it’s drug showed efficacy for ED.

Shares are at 1.07 and climbing.

Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia

https://www.businesswire.com/news/home/20220624005117/en/Can-Fite%E2%80%99s-CF602-Reverses-Erectile-Dysfunction-in-Diabetic-Pre-clinical-Model-Study-Published-in-Peer-Reviewed-Journal-Andrologia

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced its study titled “A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model” was published in the peer-reviewed journal Andrologia.